Researchers Report Fewer Relapses in Multiple Sclerosis with Off-Label Drug (rituximab)
July 2022 …
DMT for Multiple Sclerosis Tied to Lower Risk for In-Hospital COVID-19 Mortality
Mortality among patients with multiple sclerosis (MS) hospitalized for COVID-19 was lower among patients taking disease-modifying therapy (DMT), according to…
Stuart Schlossman
A compass to MS Care Rural America – from Lynchburg, VA
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?
June 8, 2022 – Mary Stroka The most frequent AEs were flushing (32.3%), nasopharyngitis (24.6%), and MS relapse during treatment with…
Stuart Schlossman
Biogen Secures Tecfidera Patent in EU Until 2028
Biogen has secured a new patent in Europe covering the use of its oral therapy Tecfidera (dimethyl fumarate) for multiple sclerosis (MS) through 2028,…
Stuart Schlossman
An MS Journey – Understanding Aspects of Specialty Pharmacy, Step Therapy & more (renewed from Sept 2019)
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
Boster Video: New MS Medication Class [2022] (BTK Inhibitors)
Share with as many people as possible as ALL with MS, will benefit from listening to this video Visit our…
Stuart Schlossman
The first decade of biosimilars – and beyond
Information showing is for meds released in recent years and for many still to come. March 2017 Ahead of this…
Stuart Schlossman
8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment
by Marta Figueiredo PhD | April 12, 2022 BREAKING NEWS Based on findings from the first two secondary progressive multiple sclerosis (SPMS)…
Stuart Schlossman
Smell Test Might Help Predict if MS Treatments Are Working
A measure of the nose’s sensitivity to smell could be used to detect whether treatments for relapsing multiple sclerosis (MS) are…
Stuart Schlossman
